Direct Oral Anticoagulants and Coronary Artery Disease

[Argirios Argiriou]

Originally Published 17 March 2022
Arteriosclerosis, Thrombosis, and Vascular Biology
Volume 42, Number 5
Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος


Highlights
•   
The benefits of direct oral anticoagulants in patients with coronary artery disease without an indication for oral anticoagulation are still debated.
•   
The combination of direct oral anticoagulants and antiplatelet medications can increase the bleeding risk in patients and a thorough risk and benefit assessment needs to be considered.
•   
In patients with atrial fibrillation and stable coronary artery disease, newer guidelines recommend continuation of direct oral anticoagulants without the addition of an antiplatelet agent.
•   
Other novel anticoagulants which have inherently lower bleeding risks while retaining ischemic benefits may soon become available.

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος